alopecia areata

Usually when you're about to walk out the door after an... 30 minutes talking about something else.

But suddenly, okay, we're talking about androgenetic alopecia, telogen effluvium, alopecia areata, half a dozen scarring alopecias, traction, trichotillomania, and they can all start with basically the same chief complaint of my hair's coming out.

So we're going to build the framework first, recognize the patterns, and then talk what you should actually do with them.

And later on, we'll have more in-depth episodes on each of these alopecias.

They may be miniaturized or prematurely cycling through the different phases or under an autoimmune attack, but the follicle is still there.

But once it's replaced by a scar, that follicle isn't coming back.

So for our non-scarring alopecias, we have like androgenic alopecia, alopecia areata, telogen effluvium, early traction, trichotillomania.

And then on scarring, you have things like lichen planopilaris or LPP, frontal fibrosing alopecia or FFA, CCCA, DLE, folliculitis decalvans, dissecting cellulites to the scalp.

However, the retrospective single-population dermoscopy-only resident-only design warrants prospective multi-center validation such as practice in experienced dermatologists before routine clinical adoption.

Our next study is published in Pediatric Dermatology titled Depictions of Alopecia in Children's Animated Films, a cross-studio analysis by Carly Needle Lawrence, Derek Imaz, Archie J. Spindler, Adol.

Children with alopecia often experience significant psychosocial challenges, and portrayals of hair loss in animated films may influence their perceptions of themselves and others.

In this study, researchers reviewed 139 full-length films from Disney, Pixar, DreamWorks, and Studio Ghibli.

Overall, simple low-cost changes including using blue drapes, positioning the surgical lamp behind the surgeon, and increasing working distance when clinically feasible may help reduce reflected light exposure during Mohs surgery.

These strategies could improve surgeon comfort and occupational eye health without compromising surgical visualization.

Now we have a study in the Journal of Cosmetic Dermatology titled Treatment Efficacy for Androgenetic Alopecia, Combination Therapy of Clinical Low-Level Laser Therapy and Proprietary Hair Growth Serum, a pilot study by Garrett Nee, Megan Stolzgaver, Gabriel Cahill, et al.

Androgenetic alopecia is a non-scarring pattern hair loss impacting up to 50% of men and women by age 50.

So I thought that was very, very good.

In the August issue of JAMA Dermatology, there was a study actually detailing two parallel phase three studies looking at upadacitinib for alopecia areata.

That is not yet approved.

There are other, three other JAK inhibitors approved for alopecia areata, but this is looking at this drug, which I think we're more familiar with its use in eczema, but it was pretty darn good at 24 weeks at the lower dose, 15 milligrams a day.

About a third of the patients achieved a SALT score under or equal to 10, means 90% regrowth.

And at the higher dose, 30 milligrams per day, about a half achieved a SALT score of 10 or less.

And that's all compared to 1% of placebo.

So it looks like this drug, which we're familiar with from using it for eczema, might be quite good for alopecia areata.

First team all hats.

First team all Alopecia.

First team all Baja.

Charlie Villanueva.

And then she was like, yeah, well, when I'm a bit stressed, it can make it worse.

But this has been like, And that is called alopecia areata.

That's exactly that.

Yeah, it was.

So I think it's worth it.

One's about a phase three program for JAK inhibitor and severe alopecia areata.

And the other is a randomized trial asking a deceptively simple question, which is, can you just let a surgical wound get wet?

Yeah, two ends of the evidence spectrum here.

Both good medicine, both worth our time in different ways.

The first

is a paper by Mostagimi et al., hepatocidinib for severe alopecia areata in adults and adolescents.

This is the UPAA1 and the UPAA2 trials.